User login
Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.
Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).
Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.
Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.
Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.
Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.
Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).
Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.
Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.
Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.
Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.
Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).
Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.
Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.
Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.